DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/3fgvvf/apriso) has announced the addition of the "Apriso (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering.
During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's (J&J's) Simponi and Takeda's Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.
Apriso features an Intellicor-coated gel suspension of mesalamine. The Intellicor coating that enables the release of mesalamine exclusively in the colon, dissolving at pH =6. Therefore, the entire mesalamine concentration of the pill formulation is successfully administered to the colon, unlike a conventional mesalamine formulation, which would be partly depleted in the acidic environment of the stomach or mostly absorbed in the jejunum (the middle portion of the small intestine that connects the duodenum and the ileum, which are not part of the colon).
- Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Apriso including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Apriso for the top six countries from 2012 to 2022.
Sales information covered for the US, Germany, Spain, the UK, China
Key Topics Covered:
1 Table of Contents
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Apriso (mesalamine)
For more information visit http://www.researchandmarkets.com/research/3fgvvf/apriso